Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks

Journal of Infection and Chemotherapy

Volumn 17, Issue 3, 2011, Pages 302-317

  Tomioka, Haruaki ^a   Tatano, Yutaka ^a   Sano, Chiaki ^a   Shimizu, Toshiaki ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Antituberculous drugs; Cytokine networks; Drug targets; Macrophages; Mycobacterial infections; Protective immunity; T lymphocytes

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; COLONY STIMULATING FACTOR 1; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 27; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; MIGRATION INHIBITION FACTOR; PROTEIN SERINE THREONINE KINASE; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSFORMING GROWTH FACTOR BETA; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG TARGETING; GENE IDENTIFICATION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TUBERCULOSIS;

EID: 80051600893     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-010-0177-y     Document Type: Review

References (118)

1. World Health Organization. Global tuberculosis control. A short update to the 2009 report. 2009. (http://www.who.int/tb/publications/global-report/2009/ update/tbu-9.pdf.
2. World Health Organization. A ministerial meeting of high M/XDR-TB burden countries: the key bottlenecks hampering the prevention and scale-up of M/XDR-TB control and patient care. 2009. (http://www.who.int/tb/challenges/mdr/ bottlenecks/bottlenecks-full-version.pdf).
3. O'Brien RJ, Vernon AA. New tuberculosis drug development. How can we do better? Am J Respir Crit Care Med. 1998;157:1705-7. (Pubitemid 28311249)
4. Janin YL. Antituberculosis drugs: ten years of research. Bioorg Med Chem. 2006;15:2479-513.
5. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des. 2006;12:4047-70. (Pubitemid 44669760)
6. Tomioka H, Tatano Y, Yasumoto K, Shimizu T. Recent advances in anti-tuberculous drug development and novel drug targets. Expert Rev Respir Med. 2008;2:455-71.
7. Hingley-Wilson SM, Sly LM, Reiner NE, MaMaster WR. The immunobiology of the mycobacterial infected macrophage. Mod Asp Immunobiol. 2000;1:96-101.
8. Tomioka H. Adjunctive immunotherapy of mycobacterial infections. Curr Pharm Des. 2004;10:3297-312. (Pubitemid 39276617)
9. Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev. 2008;226:191-204.
10. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009;27:393-422.
11. Cooper AM. T cells in mycobacterial infection and disease. Curr Opin Immunol. 2009;21:378-84.
12. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon-γ to Mycobacterium tuberculosis infection. J Exp Med. 1993;178:2249-54. (Pubitemid 23344886)
13. Dupuis S, Döffinger R, Picard C, Fieschi C, Altare F, Jouanguy E, et al. Human interferon-γ-mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion. Immunol Rev. 2000;178:129-37. (Pubitemid 32095226)
14. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for lymphotoxin. J Immunol. 1999;162:3504-11. (Pubitemid 29313602)
15. Sato K, Tomioka H, Shimizu T, Gonda T, Ota F, Sano C. Type II alveolar cells play roles in macrophage-mediated host innate resistance to pulmonary mycobacterial infections by producing proinflammatory cytokines. J Infect Dis. 2002;185:1139-47. (Pubitemid 34297772)
16. Saunders BM, Frank AA, Orme IM, Cooper AM. Interleukin-6 induced early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun. 2000;68:3322-6. (Pubitemid 30340426)
17. Fairbairn IP. Macrophage apoptosis in host immunity to mycobacterial infections. Biochem Soc Trans. 2004;32:496-8. (Pubitemid 38813547)
18. Porcelli SA, Jacobs WR Jr. Tuberculosis: unsealing the apoptotic envelope. Nat Immunol. 2008;9:1101-12.
19. 7) receptors. Immunity. 1997;7:433-44. (Pubitemid 27446017)
20. Duan L, Gan H, Arm J, Remold HG. Cytosolic phospholipase A2 participates with TNF-α in the induction of apoptosis of human macrophages infected with Mycobacterium tuberculosis H37Ra. J Immunol. 2001;166:7469-76. (Pubitemid 32525625)
21. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, Fenton MJ, et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun. 1997;65:298-304. (Pubitemid 27008937)
22. Gan H, Lee J, Ren F, Chen M, Kornfeld H, Remold HG. Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence. Nat Immunol. 2008;9:1189-97.
23. Sutterwala FZ, Mosser DM. The taming of IL-12: suppressing the production of proinflammatory cytokines. J Leukoc Biol. 1999;65:543-51. (Pubitemid 29227044)
24. Jo EK, Yang CS, Choi CH, Harding CV. Intracellular signalling cascades regulating innate immune responses to Mycobacteria: branching out from Toll-like receptors. Cell Microbiol. 2007;9:1087-98. (Pubitemid 46547129)
25. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, et al. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science. 1999;285:732-6.
26. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21:317-37.
27. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med. 1997;186:39-45. (Pubitemid 27304845)
28. Feng CG, Jankovic D, Kullberg M, Cheever A, Scanga C, Hieny S, et al. Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol. 2005;174:4185-92. (Pubitemid 40395997)
29. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998;280:1432-5. (Pubitemid 28264836)
30. Yoshida A, Koide Y, Uchijima M, Yoshida TO. Dissection of strain difference in acquired protective immunity against Mycobacterium bovis Calmette-Guérin bacillus (BCG). Macrophages regulate the susceptibility through cytokine network and the induction of nitric oxide synthase. J Immunol. 1995;155:2057-66.
31. Saunders BM, Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun. 1995;63:4011-5.
32. Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun. 1998;66:1277-81. (Pubitemid 128471479)
33. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593-623. (Pubitemid 29241135)
34. Medzhitov R, Janeway C Jr. The Toll receptor family and microbial recognition. Trends Microbiol. 2000;8:452-6.
35. Schäfer G, Jacobs M, Wilkinson RJ, Brown GD. Non-opsonic recognition of Mycobacterium tuberculosis by phagocytes. J Innate Immun. 2009;1:231-43.
36. Hu C, Mayadas-Norton T, Tanaka K, Chan J, Salgame P. Mycobacterium tuberculosis infection in complement receptor 3-deficient mice. J Immunol. 2000;165:2596-602. (Pubitemid 30660706)
37. Khader SA, Cooper AM. IL-23 and IL-17 in tuberculosis. Cytokine. 2008;41:79-83.
38. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-25.
39. Cooper AM, Kipnis A, Turner J, Magram J, Ferrante J, Orme IM. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol. 2002;168:1322-7. (Pubitemid 34094502)
40. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc Natl Acad Sci USA. 2004;101:4560-5. (Pubitemid 38437450)
41. Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γ responses if IL-12p70 is available. J Immunol. 2005;175:788-95. (Pubitemid 41094960)
42. H17 lineage. Nature (Lond). 2006;441:231-4.
43. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179-89. (Pubitemid 43214587)
44. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31:331-41.
45. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev. 2007;6:169-75. (Pubitemid 46187336)
46. Greenstein RJ. Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis. 2003;3:507-14. (Pubitemid 36919097)
47. Dow CT. Paratuberculosis and type I diabetes: is this the trigger? Med Hypotheses. 2006;67:782-5. (Pubitemid 44062142)
48. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology. 2009;126:177-85.
49. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, Kawakami K, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol. 2007;178:3786-96. (Pubitemid 46417647)
50. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, Kishihara K, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol. 2010;184:4414-22.
51. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007;8:369-77. (Pubitemid 46745412)
52. H17 cells. Nature (Lond). 2008;453:1051-7. (Pubitemid 351871737)
53. Wozniak TM, Ryan AA, Triccas JA, Britton WJ. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun. 2006;74:557-65. (Pubitemid 43023111)
54. Robinson CM, Nau GJ. Interleukin-12 and interleukin-27 regulate macrophage control of Mycobacterium tuberculosis. J Infect Dis. 2008;198:359-66.
55. Pearl JE, Khader SA, Solache A, Gilmartin L, Ghilardi N, de Sauvage F, et al. IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J Immunol. 2004;173:7490-6. (Pubitemid 39628189)
56. Hölscher C, Hölscher A, Rückerl D, Yoshimoto T, Yoshida H, Mak T, et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol. 2005;174:3534-44. (Pubitemid 40354062)
57. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15:985-95. (Pubitemid 34075378)
58. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol. 2002;169:443-53. (Pubitemid 34686166)
59. Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med. 2002;80:147-62. (Pubitemid 34230635)
60. Sugawara I, Yamada H, Kaneko H, Mizuno S, Takeda K, Akira S. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun. 1999;67:2585-9. (Pubitemid 29200522)
61. Vankayalapati R, Wizel B, Weis SE, Samten B, Girard WM, Barnes PF. Production of interleukin-18 in human tuberculosis. J Infect Dis. 2000;182:234-9. (Pubitemid 30497809)
62. Schneider BE, Korbel D, Hagens K, Koch M, Raupach B, Enders J, et al. A role for IL-18 in protective immunity against Mycobacterium tuberculosis. Eur J Immunol. 2010;40:396-405.
63. Fenton MJ, Vermeulen MW, Kim S, Burdick M, Strieter RM, Kornfeld H. Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis. Infect Immun. 1997;65:5149-56. (Pubitemid 27513563)
64. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med. 1998;187:2103-8. (Pubitemid 28285581)
65. Robinson CM, O'Dee D, Hamilton T, Nau GJ. Cytokines involved in interferon-gamma production by human macrophages. J Innate Immun. 2009;2:56-65.
66. Maeurer MJ, Trinder P, Hommel G, Walter W, Freitag K, Atkins D, et al. Interleukin-7 or interleukin-15 enhances survival of Mycobacterium tuberculosis-infected mice. Infect Immun. 2000;68:2962-70. (Pubitemid 30253878)
67. Juffermans NP, Florquin S, Camoglio L, Verbon A, Kolk AH, Speelman P, et al. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J Infect Dis. 2000;182:902-8.
68. Yamada H, Mizumo S, Horai R, Iwakura Y, Sugawara I. Protective role of interleukin-1 in mycobacterial infection in IL-1 a/b double-knockout mice. Lab Invest. 2000;80:759-67. (Pubitemid 30340660)
69. Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol. 2007;179:8098-104.
70. Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LV, et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol. 2009;183:6639-45.
71. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFa. Immunity. 2005;22:131-42.
72. Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA, et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol. 2010;184:3830-40.
73. Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther. 2006;8:R166.
74. Rook GA. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med. 2007;7:327-37. (Pubitemid 46767790)
75. Masters SL, Mielke LA, Cornish AL, Sutton CE, O'Donnell J, Cengia LH, et al. Regulation of interleukin-1beta by interferongamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep. 2010;11:640-6.
76. Chensue SW, Warmington K, Ruth JH, Lukacs N, Kunkel SL. Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-γ and IL-4 knockout mice. Analysis of local and regional cytokine and chemokine networks. J Immunol. 1997;159:3565-73. (Pubitemid 127482116)
77. North RJ. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol. 1998;113:55-8. (Pubitemid 28329065)
78. McKenzie AN, Zurawski G. Interleukin-13: characterization and biologic properties. Cancer Treat Res. 1995;80:367-78.
79. Murray PJ, Young RA. Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect Immun. 1999;67:3087-95. (Pubitemid 29244734)
80. Reljic R, Stylianou E, Balu S, Ma JK. Cytokine interactions that determine the outcome of mycobacterial infection of macrophages. Cytokine. 2010;51:42-6.
81. Kim JY, Kim HJ, Hurt EM, Chen X, Howard OM, Farrar WL. Functional and genomic analyses of FOXP3-transduced Jurkat-T cells as regulatory T (Treg)-like cells. Biochem Biophys Res Commun. 2007;362:44-50. (Pubitemid 47299321)
82. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Regulatory T cells and human disease. Clin Dev Immunol 2007;2007:89195-206.
83. Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev. 2005;4:351-63. (Pubitemid 41080072)
84. Battaglia M, Gregori S, Bacchetta R, Roncarolo MG. Tr1 cells: from discovery to their clinical application. Semin Immunol. 2006;18:120-7. (Pubitemid 43248740)
85. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med. 2006;173:803-10.
86. Babu S, Bhat SQ, Kumar NP, Kumaraswami V, Nutman TB. Regulatory T cells modulate Th17 responses in patients with positive tuberculin skin test results. J Infect Dis. 2010;201:20-31.
87. Vodovotz Y, Geiser AG, Chesler L, Letterio JJ, Campbell A, Lucia MS, et al. Spontaneously increased production of nitric oxide in the transforming growth factor β1 null mouse. J Exp Med. 1996;183:2337-42.
88. Warwick-Davies J, Lowrie DB, Cole PJ. Selective deactivation of human monocyte functions by TGF-β. J Immunol. 1995;155:3186-93.
89. Sano C, Sato K, Shimizu T, Kajitani H, Kawauchi H, Tomioka H. The modulating effects of proinflammatory cytokines interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α), and immunoregulating cytokines IL-10 and transforming growth factor-β (TGF-β), on anti-microbial activity of murine peritoneal macrophages against Mycobacterium avium-intracellulare complex. Clin Exp Immunol. 1999;115:435-42. (Pubitemid 29130357)
90. Lingnau K, Hoehn P, Kerdine S, Koelsch S, Neudoerfl C, Palm N, et al. IL-4 in combination with TGF-β favors an alternative pathway of Th1 development independent of IL-12. J Immunol. 1998;61:4709-18. (Pubitemid 28492046)
91. Tomioka H, Sato K, Shimizu T, Sano C, Akaki T, Saito H, et al. Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother. 1997;41:357-62. (Pubitemid 27111031)
92. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol. 2007;8:1380-9. (Pubitemid 350131175)
93. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24:677-88. (Pubitemid 43867371)
94. H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967-74. (Pubitemid 47300011)
95. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8:942-9. (Pubitemid 47300008)
96. H17 cells. Nature (Lond). 2008;454:350-2.
97. Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, et al. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med. 2007;204:161-70. (Pubitemid 46148766)
98. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006;7:929-36. (Pubitemid 44263906)
99. Kawai T, Akira S. Signaling to NF-κB by Toll-like receptors. Trends Mol Med. 2007;13:460-9.
100. Mdluli K, Spigelman M. Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol. 2006;6:459-67. (Pubitemid 44340669)
101. Williams KJ, Duncan K. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr Mol Med. 2007;7:297-307. (Pubitemid 46767787)
102. Tomioka H. Development of new antituberculous agents based on new drug targets and structure-activity relationship. Expert Opin Drug Discov. 2008;3:1-29.
103. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant. 2009;24:1429-35.
104. Mamane Y, Sharma S, Petropoulos L, Lin R, Hiscott J. Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity. 2000;12:129-40. (Pubitemid 30398627)
105. Nair S, Ramaswamy PA, Ghosh S, Joshi DC, Pathak N, Siddiqui I, et al. The PPE18 of Mycobacterium tuberculosis interacts with TLR2 and activates IL-10 induction in macrophage. J Immunol. 2009;183:6269-81.
106. Brodin P, Rosenkrands I, Andersen P, Cole ST, Brosch R. ESAT-6 proteins: protective antigens and virulence factors? Trends Microbiol. 2004;12:500-8. (Pubitemid 39370732)
107. Pathak SK, Basu S, Basu KK, Banerjee A, Pathak S, Bhattacharyya A, et al. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat Immunol. 2007;8:610-8. (Pubitemid 46785125)
108. Wang X, Barnes PF, Dobos-Elder KM, Townsend JC, Chung YT, Shams H, et al. ESAT-6 inhibits production of IFN-γ by Mycobacterium tuberculosis- responsive human T cells. J Immunol. 2009;182:3668-77.
109. Chao J, Wong D, Zheng X, Poirier V, Bach H, Hmama Z, et al. Protein kinase and phosphatase signaling in Mycobacterium tuberculosis physiology and pathogenesis. Biochim Biophys Acta (BBA) Proteins Proteomics. 2009;1804:620-7.
110. Koul A, Herget T, Klebl B, Ullrich A. Interplay between mycobacteria and host signalling pathways. Nat Rev Microbiol. 2004;2:189-202. (Pubitemid 39490082)
111. Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C, Huygen K, et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science. 2004;304:1800-4. (Pubitemid 38787896)
112. Philips JA. Mycobacterial manipulation of vacuolar sorting. Cell Microbiol. 2008;10:2408-15.
113. Székely R, Wáczek F, Szabadkai I, Németh G, Hegymegi-Barakonyi B, Eros D, et al. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Immunol Lett. 2008;116:225-31.
114. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, Ledwidge R, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322:1392-5. (Pubitemid 352775253)
115. Shimizu T, Tomioka H, Sato K, Sano C, Akaki T, Dekio S, et al. Effects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice. Antimicrob Agents Chemother. 1999;43:514-9. (Pubitemid 29109512)
116. Tomioka H, Sano C, Sato K, Ogasawara K, Akaki T, Sano K, et al. Combined effects of ATP on the therapeutic efficacy of antimicrobial drug regimens against Mycobacterium avium complex infection in mice and roles of cytosolic phospholipase A2-dependent mechanisms in the ATP-mediated potentiation of antimycobacterial host resistance. J Immunol. 2005;175:6741-9. (Pubitemid 41598918)
117. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (Lond). 1998;393:537-44. (Pubitemid 28319235)
118. Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002;184:5479-90. (Pubitemid 35024395)